Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.

Stefan BarisicElizabeth M BrahmbhattElena CherkasovaTimothy T SpearUjjawal SavaniStephanie PierreGina M ScurtiLong ChenMuna IgbokoRosa NadalGang ZengGordon ParryDavid F StroncekSteven HighfillAnnika V DalheimRobert RegerMichael I NishimuraRichard W Childs

Published in: Journal for immunotherapy of cancer (2024)

This is the first report showing that human ccRCC cells can be selectively recognized and killed by TCR-engineered T cells targeting a HERV-derived antigen. These preclinical findings provided the foundation for evaluating HERV-E TCR-transduced T cell infusions in patients with metastatic ccRCC in a clinical trial (NCT03354390).

Keyphrases

endothelial cells
clinical trial
renal cell carcinoma
regulatory t cells
induced pluripotent stem cells
cancer therapy
pluripotent stem cells
randomized controlled trial
drug delivery
dendritic cells
mesenchymal stem cells
bone marrow
cell death
binding protein
pi k akt